AstraZeneca cuts 600 US sales jobs in respiratory and immunologyAstraZeneca has eliminated approximately 600 positions from its US respiratory and immunology commercial teams as part of a three-year cost-savings initiative.Nov 13, 2026·2 sourcesAsthmaPharmaceutical patentsPharmaceutical IndustryCOPDCorporate strategyCorporate restructuringCorporate layoffs00
